HIMS expands its Weight Loss Program to the United Kingdom, bringing personalized, doctor-designed care and broader access to obesity treatments.
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
HIMS expands its tech-driven care with new diagnostics, hormonal treatments, and a Canada launch via Livewell.
| Health Care Providers & Services Industry | Healthcare Sector | Andrew Dudum CEO | NYSE Exchange | 433000106 CUSIP |
| US Country | 1,637 Employees | - Last Dividend | - Last Split | 13 Sep 2019 IPO Date |
Hims & Hers Health, Inc., based in San Francisco, California, operates as a telehealth platform connecting consumers with licensed healthcare professionals across the United States, the United Kingdom, and other international locations. The company leverages its websites and mobile application to offer a variety of carefully selected health and wellness products and services, both on prescription and over-the-counter basis. Its business model focuses on providing convenient access to ongoing healthcare services, including prescription medication refills and consultations with healthcare providers, as well as a wide range of wellness products through direct sales and wholesale partnerships.